The Dual Role of Tumor Necrosis Factor (TNF) in Cancer Biology

被引:93
作者
Bertazza, L. [1 ]
Mocellin, S. [1 ]
机构
[1] Univ Padua, Policlin Univ, Dept Oncol & Surg Sci, I-35128 Padua, Italy
关键词
Tumor necrosis factor; TNF; cancer; biology; therapy; ISOLATED LIMB PERFUSION; NF-KAPPA-B; SOFT-TISSUE SARCOMA; ISOLATED HEPATIC PERFUSION; NITRIC-OXIDE SYNTHASE; ALPHA-INDUCED APOPTOSIS; ACTIVATED PROTEIN-KINASE; RENAL-CELL CARCINOMA; LIPOSOMAL DOXORUBICIN DOXIL(R); SYNERGISTIC ANTITUMOR-ACTIVITY;
D O I
10.2174/092986710793176339
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Tumor necrosis factor (TNF) is a cytokine with well known anticancer properties and is being utilized as anticancer agent for the treatment of patients with locally advanced solid tumors. However, TNF role in cancer biology is debated. In fact, in spite of the wealth of evidence supporting its antitumor activity, the cascade of molecular events underlying TNF-mediated tumor regression observed in vivo is still incompletely elucidated. Furthermore, some preclinical findings suggest that TNF may even promote cancer development and progression. With this work we intend to summarize the molecular biology of TNF (with particular regard to its tumor-related activities) and review the experimental and clinical evidence currently available describing the complex and sometime apparently conflicting relationship between this cytokine, cancer biology and antitumor therapy. We also propose a model to explain the dual effect of TNF based on the exposure time and cytokine levels reached within the tumor microenvironment. Finally, we overview recent research findings that might lead to new ways for exploiting the anticancer potential of TNF in the clinical setting.
引用
收藏
页码:3337 / 3352
页数:16
相关论文
共 230 条
[1]   Signalling pathways of the TNF superfamily: A double-edged sword [J].
Aggarwal, BB .
NATURE REVIEWS IMMUNOLOGY, 2003, 3 (09) :745-756
[2]  
Aggarwal BB, 2000, ANN RHEUM DIS, V59, P6
[3]  
Alexander HR, 2000, CLIN CANCER RES, V6, P3062
[4]   Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver [J].
Alexander, HR ;
Bartlett, DL ;
Libutti, SK ;
Fraker, DL ;
Moser, T ;
Rosenberg, SA .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) :1479-1489
[5]   Hepatic vascular isolation and perfusion for patients with progressive unresectable liver metastases from colorectal carcinoma refractory to previous systemic and regional chemotherapy [J].
Alexander, HR ;
Libutti, SK ;
Bartlett, DL ;
Pingpank, JF ;
Kranda, K ;
Helsabeck, C ;
Beresnev, T .
CANCER, 2002, 95 (04) :730-736
[6]  
Ameloot Paul, 2004, Methods Mol Med, V98, P33
[7]  
An JB, 2003, CLIN CANCER RES, V9, P4537
[8]   Tumor necrosis factor-α in the pathogenesis and treatment of cancer [J].
Anderson, GM ;
Nakada, MT ;
DeWitte, M .
CURRENT OPINION IN PHARMACOLOGY, 2004, 4 (04) :314-320
[9]   Tumour necrosis factor-α mediates tumour promotion via a PKCα- and AP-1-dependent pathway [J].
Arnott, CH ;
Scott, KA ;
Moore, RJ ;
Hewer, A ;
Phillips, DH ;
Parker, P ;
Balkwill, FR ;
Owens, DM .
ONCOGENE, 2002, 21 (31) :4728-4738
[10]   Expression of both TNF-α receptor subtypes is essential for optimal skin tumour development [J].
Arnott, CH ;
Scott, KA ;
Moore, RJ ;
Robinson, SC ;
Thompson, RG ;
Balkwill, FR .
ONCOGENE, 2004, 23 (10) :1902-1910